Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

This study is looking for adults aged 18 or over who have Type 2 Diabetes. You would need to have moderate or severe kidney problems and your most recent blood tests should show that your blood sugar (HbA1c) is still quite high, even though you are already taking insulin. You might also be taking metformin or an SGLT2 inhibitor.

There are also some things that would mean you couldn't join. For example, if you have Type 1 Diabetes, or a history of very severe low blood sugar. Also, if you've had certain heart problems recently, or have certain types of cancer or thyroid conditions, you wouldn't be able to take part. The study also cannot include you if you've recently had surgery for weight loss or other specific medical conditions.

The research team will carefully review all your health information to make sure the study is a good fit for you and that it's safe for you to participate.

If you join this study, it will last for about 14 months. During this time, you would need to attend up to 22 visits at the study clinic. These visits will involve various checks and tests to monitor your health and how you respond to the study medicine. You will be given either the new medicine, Retatrutide, or a placebo (a dummy medicine), and neither you nor your study doctor will know which you are receiving until the end of the study. This helps to ensure the results are accurate. The research team will guide you through each step and explain everything clearly.